BofA Securities analyst Jason Gerberry maintains $Alkermes (ALKS.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 46.9% and a total average return of 2.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
A revision in the biotech sector's comparative analysis has led to the expectation of a higher valuation multiple, which has influenced the updated outlook on Alkermes. In anticipation of new data in the year 2025, there is a particular interest in the Phase 2 updates concerning narcolepsy treatments from Alkermes and Centessa.
The firm's revised outlook on Alkermes is based on an updated forecast and a sum-of-the-parts analysis. The focus of investor discussions is increasingly turning to ALKS 2680, due to its prospects of significantly impacting the $10 billion branded narcolepsy and idiopathic hypersomnia markets, particularly as the Phase 2 results are anticipated in the second half of 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Jason Gerberry維持$阿爾凱默斯 (ALKS.US)$持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為46.9%，總平均回報率為2.8%。
此外，綜合報道，$阿爾凱默斯 (ALKS.US)$近期主要分析師觀點如下：
生物技術行業比較分析的修訂導致人們對更高的估值倍數的預期，這影響了Alkermes的最新前景。預計2025年會有新的數據，因此人們對Alkermes和Centessa關於發作性睡病治療的第二階段更新特別感興趣。
該公司對Alkermes的修訂展望基於最新的預測和各部分的總和分析。投資者討論的焦點越來越多地轉向ALKS 2680，因爲ALKS 2680有可能對價值100億美元的品牌發作性睡病和特發性睡眠過度市場產生重大影響，尤其是在預計2025年下半年公佈第二階段結果的情況下。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
